Prescribers Should Restrict the Use of Non-FDA-Approved Compounded Bioidentical Hormones, Except for Specific Medical Circumstances

The use of compounded bioidentical hormone therapies (cBHTs) — an more and more well-liked approach to decrease signs or symptoms of menopause and male hypogonadism — should be confined to the smaller quantity of clients who simply cannot benefit from an Food and drug administration-authorised hormone remedy merchandise, states a new report from the Countrywide Academies of Sciences, Engineering, and Medication.

Previous post Hundreds of Elephants Have Died in Botswana, And We Don’t Know Why
Next post Dogs Necessary for Only a Few Areas of Research at Veterans Affairs – Agency Should Adopt Expanded Criteria for Using Dogs